Key result
Pre-operative use of levosimendan in high-risk patients with severely reduced left ventricular ejection fraction may reduce the requirements for postoperative inotropic and mechanical support, ICU stay, and post-operative mortality.
Why the study?
Does levosimendan improve clinical and hemodynamic outcomes in patients with decreased left ventricular function undergoing cardiac surgery?
Population
Patients with decreased left ventricular function undergoing cardiac surgery
Comparison
Levosimendan vs Conventional inotropes or placebo
Design
Review
Authors
Loading...
May support preoperative consideration in high-risk reduced-LVEF cardiac surgery; leaves open confirmation by RCTs.
Does levosimendan improve clinical and hemodynamic outcomes in patients with decreased left ventricular function undergoing cardiac surgery?
Levosimendan administered perioperatively, particularly 24 hours before surgery, may improve hemodynamics, preserve renal function, and reduce mortality and complications in cardiac surgery patients with reduced LVEF.
Bozhinovska et al. (2016) conducted a review in Decreased left ventricular function undergoing cardiac surgery. Levosimendan vs. Placebo, conventional inotropes, or intra-aortic balloon pump (IABP) was evaluated. Pre-operative use of levosimendan in high-risk patients with severely reduced left ventricular ejection fraction may reduce the requirements for postoperative inotropic and mechanical support, ICU stay, and post-operative mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: